MindWalk (HYFT) Q2 2025 earnings summary

Executive summary

• Relocated headquarters from Victoria, BC to Austin, TX to access a vibrant AI, semiconductor, and biotech ecosystem, supporting strategic growth and rebranding initiatives.

• Actively pursuing divestiture of two European wet labs to reduce redundancies, enhance efficiency, and focus on high-growth areas like the LENSai platform and Canadian lab expansion.

• Implemented cost-cutting measures, including executive compensation adjustments and no FY2024 bonuses, to align with long-term goals and financial discipline.

• ImmunoPrecise Antibodies Ltd. specializes in AI-driven and wet lab biotherapeutic discovery, integrating proprietary technologies for drug and biologic development.

• Strategic acquisitions, such as BioStrand, have enhanced AI and multi-omics capabilities, supporting innovation in antibody discovery.

Financial highlights

• Q2 FY2025 revenue was CAD 6.1 million, flat year-over-year but up 16% sequentially from Q1 FY2025; six-month revenue was $11.4 million, down 3.8%.

• Gross profit for the quarter rose 16.4% to $3.4 million, with gross margin increasing to 56% from 48% year-over-year.

• Net loss for Q2 FY2025 was CAD 2.6 million (CAD 0.09 per share), compared to a loss of CAD 2.4 million (CAD 0.10 per share) in Q2 FY2024; six-month net loss was $6.6 million, up from $5.8 million.

• BioStrand achieved record quarterly revenue of CAD 397,000, with life-to-date revenue of CAD 917,000.

• Ended Q2 FY2025 with cash of CAD 3.6 million, reflecting operational use and net financing activity; concerns about sufficiency for one year of operations.

Outlook and guidance

• Expecting faster growth and higher margins post-divestiture, with capital redeployed to high-growth, high-margin areas like BioStrand and LENSai.

• Anticipate BioStrand to exit the year at a much higher revenue run rate as early access users convert to paying clients.

• AWS marketplace launch for LENSai anticipated by March, with progressive rollout of analytical pipelines.

• Management focuses on revenue growth, asset enhancement, and shareholder value, aiming to lead in AI-driven antibody discovery.

• Liquidity concerns persist, with the need for additional financing to support operations and growth plans.